Background
==========

COPD is one of the leading health burdens worldwide and has been estimated to become the third leading cause of death by 2030.[@b1-copd-12-3371] In Hong Kong (HK), 10.7% of the populations are chronic smokers.[@b2-copd-12-3371] Based on the Epidemiology and Impact of COPD (EPIC) Asia survey by Lim et al,[@b3-copd-12-3371] the estimated prevalence of stable COPD was 7.7%, and 16.1% in these COPD patients met the definition of severe symptomatic phenotype. In the same study, a significant proportion of these COPD patients also reported "very poor" to "fair" general health status and unplanned health care utilization.[@b3-copd-12-3371] In 2005, COPD was the third leading cause of respiratory mortality and ranked second as a respiratory cause of hospitalization and inpatient bed-days in HK.[@b4-copd-12-3371] In the US, the hospitalizations and readmissions for acute exacerbation of COPD (AECOPD) are prevalent and costly.[@b5-copd-12-3371],[@b6-copd-12-3371]

To meet the rising cost and quality of COPD care, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline was first released in 2001. Since its publication, it quickly became an important reference for COPD treatment. There was a major revision of the GOLD guideline in 2011, with incorporation of functional level and risk of future exacerbation,[@b7-copd-12-3371] based on the fact that COPD is a disease with multifaceted nature and the management plan should not rely on airflow limitation alone. According to the spirometric parameters, history of recent exacerbation, functional status in terms of modified Medical Research Council (mMRC) score or COPD Assessment Test (CAT) score, COPD patients are categorized into groups A to D accordingly ([Figure 1](#f1-copd-12-3371){ref-type="fig"}). Within each group of patients, a set of medications are recommended for disease control and prevention of exacerbation. Bronchodilators (BDs), especially long-acting agents, are considered as the backbone of pharmacological treatment, either as first-line or alternative choices.

The attending physicians may not always adhere to the guideline, as seen in other common medical conditions.[@b8-copd-12-3371] Despite the availability of the GOLD guideline and its recommendation of stage-based pharmacotherapy, many studies showed inadequate adherence.[@b9-copd-12-3371]--[@b12-copd-12-3371] Reasons including poor familiarity with the GOLD guideline and difficulty in assessing response to therapy may contribute to suboptimal guideline adherence.[@b12-copd-12-3371],[@b13-copd-12-3371] It was reported that guideline-oriented pharmacotherapy might improve airflow limitation and lower health care cost.[@b14-copd-12-3371],[@b15-copd-12-3371]

In addition, COPD is associated with various respiratory and non-respiratory comorbidities, which impose negative impacts on patients, leading to impaired functional status and a higher mortality rate.[@b16-copd-12-3371] Scattered reports on the prevalence of COPD comorbidities in HK have been published, but data from large-scale studies are lacking.[@b17-copd-12-3371],[@b18-copd-12-3371]

The primary objective of the current study was to evaluate the adherence rate of pharmacological treatment to the GOLD guideline published in 2011 in HK. The secondary objective was to investigate the prevalence of comorbidities among COPD patients in the local public hospitals.

Methods
=======

Study design and patient recruitment
------------------------------------

This 12-month, multicenter observational study was conducted in five public hospitals with tertiary referral clinics in HK between March 2013 and February 2015. Consecutive patients were recruited from outpatient clinics of these hospitals if a diagnosis of COPD was made according to the GOLD guideline and results of spirometry testing were either available within 6 months prior to study enrollment or could be performed at the baseline visit. Concurrent participation in another clinical trial was the only exclusion criterion. Informed consents were obtained from the patients or provided by a legally acceptable representative of the patient if they were incapable of doing so. The study was approved by the corresponding ethics committees of the participating hospitals (The Joint Chinese University of Hong Kong -- New Territories East Cluster Clinical Research Ethics Committee, Research Ethics Committee \[Kowloon Central/Kowloon East\] and Kowloon West Cluster Research Ethics Committee).

The observational period of 12 months covered three clinic visits every 6 months for each patient. In the baseline visit (visit 1), patients were treated according to the attending physicians' decision and baseline clinical data were collected. The second (visit 2) and final (visit 3) visits were conducted at months 6 and 12, respectively. As this study was designed to reflect the real-life setting of clinical practice, the assignment of the patient to the therapy would be decided by the attending physicians and not predefined by the study protocol. In order to evaluate the adherence to the GOLD guideline 2011, COPD treatment, concomitant medications, adjustment of medication, reasons of treatment change and use of rescue medications were recorded. Throughout the study period, the occurrence of exacerbations and death were recorded. Spirometric measurements were performed according to the criteria recommended by the American Thoracic Society and referenced according to the Global Lung Function Initiative spirometric prediction equations.[@b19-copd-12-3371],[@b20-copd-12-3371]

Sample size calculation
-----------------------

An earlier study estimated that 139,000 moderate or severe COPD cases in people aged ≥30 years occurred in HK using a COPD prevalent model, which implied a 3.5% prevalence rate.[@b21-copd-12-3371] The sample size calculation was based on precision approach. We planned a random sample to seek a 95% confidence interval (CI) that the sample was representative of the COPD population in HK. As this was a measure of adherence of a new guideline, the rate of adherence was uncertain and conservatively assumed to be 50%. Assuming a 95% CI, margin of error of 5% and variability of a rate of 50%, the estimated sample size would be 385. Considering an attrition rate of 10% during the study, a total of 428 subjects were required.

Statistical analysis
--------------------

Baseline characteristics including demographic data, spirometric parameters and history of exacerbations of patients were summarized by descriptive statistics. Continuous variables were represented by mean and median, and categorical data were represented by values in percentage. The status of guideline adherence was stratified into adherent, overtreated and undertreated groups. The combinations of pharmacological treatment of each group are listed in [Table 1](#t1-copd-12-3371){ref-type="table"}. The number of COPD exacerbation episodes throughout the 12 months was collected for those patients with the same status of guideline compliance across visits 1 and 2. The Mann--Whitney *U* test was used to compare the number of exacerbations between adherent, overtreated and undertreated groups. Linear regression analysis with adjustment of confounding variables was performed if any significant association was found between treatment adherence status and exacerbation rate over 12 months. For the incidence of different comorbidities among individual COPD groups, they were compared using the chi-square test. All tests were two tailed, and significance was set at 0.05. Data analyses were performed with IBM SPSS Statistics software version 22.0.

Results
=======

A total of 450 patients were recruited from the respiratory clinics of five hospitals. After 12 months of observation, 68 (15.1%) patients dropped out from the study. Approximately half (34, 54.0%) of the patients died, and approximately one-third (19, 30.2%) of them were lost to follow-up ([Figure 2](#f2-copd-12-3371){ref-type="fig"}).

Patient characteristics
-----------------------

Baseline demographics are shown in [Table 2](#t2-copd-12-3371){ref-type="table"}. The mean number of AECOPD before enrollment was 1.6±1.9 episodes, and \~60% of patients belonged to GOLD group D according to the guideline classification.

Treatment characteristics
-------------------------

The frequency of COPD medication use is shown in [Table 3](#t3-copd-12-3371){ref-type="table"}. Short-acting β~2~-agonist (SABA) was the most commonly prescribed inhaler with \>85% of groups B, C and D patients having received it throughout the study period. Inhaled corticosteroids (ICS) alone were not commonly used in groups A and B patients. However, ICS was used in combination, especially with long-acting β~2~-agonist (LABA), contributing to a high rate of prescription in all COPD stages. Except for patients in groups A and C, the use of ICS in COPD patients could be up to \>80%. Among different BDs, the use of any LABA outweighed the use of any long-acting muscarinic antagonist (LAMA) most of the time. More than 50% of patients received LABA at each visit, with an increasing trend observed. The rate of LABA use approached 90% among group D patients. Such a high rate of LABA prescription was mainly due to the use of LABA/ICS combination. Theophylline was quite commonly used, but roflumilast was rarely used in the 12-month period.

Physicians could adjust the treatment at each clinical visit according to the medical need ([Table 4](#t4-copd-12-3371){ref-type="table"}). Among those who had changed treatment, the most common reason was insufficient disease control.

Primary objective
-----------------

### Guideline adherence on pharmacological treatment

There was a decreasing trend for the adherence rate throughout this 12-month study, with 58.2% at baseline, 47.7% at month 6 and 51.6% at month 12 ([Table 5](#t5-copd-12-3371){ref-type="table"}). The guideline adherence was mainly observed in group D patients, with \>95% of treatment compliance falling within this group of patients.

Although both undertreatment and overtreatment contributed to guideline nonadherence, the overtreatment group shared a greater proportion. More patients were undertreated in group B than those in group D (*p*\<0.001), and group B patients contributed to \>90% of the proportion in the over-treatment group at all three visits. A significant proportion of overtreatment was due to the use of ICS, either alone or together with LABA, in patients of groups A and B.

### Association between guideline adherence and AECOPD

Adherent group patients had significantly more episodes of AECOPD when compared with the overtreated group (*p*\<0.001) and undertreated group (*p*\<0.001). The figures are shown in [Table 6](#t6-copd-12-3371){ref-type="table"}. Analysis was performed and confirmed significant associations between COPD GOLD grouping, frequency of AECOPD 1 year prior to study enrollment, treatment adherence and subsequent episodes of AECOPD. After adjustment for COPD GOLD grouping and frequency of AECOPD 1 year prior to study enrollment, patients who were treated according to guideline had more episodes of AECOPD than those who were undertreated (*p*\<0.001). However, there was no association between overtreatment and exacerbation rate over 1 year (*p*=0.593).

Secondary objectives
--------------------

In all, 364 (80.9%) patients had coexisting comorbidities at the baseline visit ([Table 7](#t7-copd-12-3371){ref-type="table"}), and hypertension (HT) was the most common single disease (40.7%). Patients who were in groups B and D at baseline had higher prevalence of comorbidities (74.4% and 85.3%, respectively) than those in COPD groups A and C at baseline (60.0% and 75.0%, respectively; *p*=0.035). Group D patients had more coexisting heart failure than group B patients.

Discussion
==========

This 12-month observational study reflects the local prescription pattern of pharmacological treatment in the hospital respiratory clinic setting. The baseline patient characteristics were comparable with other local and international COPD studies, which comprised mainly male heavy smokers, with similar body mass index (BMI) and forced expiratory volume in 1 second (FEV~1~) levels.[@b18-copd-12-3371],[@b22-copd-12-3371]--[@b24-copd-12-3371] The spectrum of COPD included patients of groups A--D, with a distribution skewed toward the categories with more symptoms (groups B and D) with relatively high mMRC and CAT scores. This finding is different from the data obtained in the EPIC Asia population-based study, which was mainly a cross-sectional population-based survey.[@b3-copd-12-3371] Instead, this type of patient distribution has been observed in the FLAME trial.[@b25-copd-12-3371]

To date, this has been the only large-scale observational study in HK investigating the treatment adherence to GOLD guideline 2011 on COPD patients. The adherence rate shown in this study was suboptimal, although there was no standard threshold of satisfactory adherence. The adherence rate to the GOLD guideline 2011 varied from 18.0% to 70.1% for various overseas studies.[@b22-copd-12-3371],[@b26-copd-12-3371]--[@b28-copd-12-3371] The main reason for guideline nonadherence in the current study was due to overtreatment, especially the overuse of ICS in low-risk patients alone or in combination with other BDs, which had also been reported in a Turkish study.[@b22-copd-12-3371] Long-acting BDs were indicated for group B patients, but they were underutilized. More than 65% of group B patients received LABA/ICS combination, but only a minor proportion of them received single or combined long-acting BDs. The widespread use of LABA/ICS combination may be explained by its longer marketing history and better availability in the public health care system, contributing to a much higher utilization rate than LAMA or LABA monotherapy. Concerns of ICS overuse have been studied frequently in the last few years, especially for its inferior efficacy of bronchodilation and higher risk of causing pneumonia.[@b29-copd-12-3371],[@b30-copd-12-3371]

The pattern of oral pharmacological treatment in the current study is different from other studies. Quite a number of patients received oral theophylline during the study period. When comparing with other inhaled BDs, theophylline was much cheaper and its prescription was not restricted by the public health care system. Despite having more systemic side effects, it was an attractive choice of treatment across all four groups of local COPD patients. The use of roflumilast in patients of groups A and B is obviously out of the guideline recommendations, which suggested use of roflumilast in patients of groups C and D. Although this practice was uncommon in the current study, it might reflect inadequate understanding of its indications.

The adherence rate to the GOLD guideline was shown to be variable by several studies.[@b9-copd-12-3371]--[@b11-copd-12-3371] Nonadherence rates were reported in these studies, but only a few of them subdivided the types of nonadherence into categories of under- or overtreatment.[@b26-copd-12-3371],[@b28-copd-12-3371] The underlying reasons for guideline non-adherence were not evaluated in this study. We postulated that this would be due to inadequate symptom evaluation and suboptimal understanding of guideline recommendations.

The lack of adherence to clinical guidelines had been published before, and some of the barriers were due to the guideline itself.[@b31-copd-12-3371] With regular updates based on the latest evidence, some of these problems can be solved or minimized. However, many obstacles for GOLD guideline adherence were reported, including inadequate familiarity of guideline, lack of perceived treatment benefit, low self-efficacy and time constraints.[@b12-copd-12-3371],[@b32-copd-12-3371] Multiple strategies have been advocated in different countries to enhance the guideline adherence and physician awareness, leading to various degrees of success.[@b9-copd-12-3371],[@b12-copd-12-3371],[@b33-copd-12-3371] Unfortunately, such data are lacking in HK, and further study in this area is highly warranted.

The majority of the patients within the adherent group belonged to group D, with a higher intrinsic risk of recurrent exacerbations. After the adjustment of other confounding variables, including COPD groupings and history of AECOPD 1 year before study enrollment, the guideline adherence status was not associated with subsequent risk of AECOPD.

Various comorbidities are commonly associated with COPD. As recommended in the GOLD guideline, management of COPD patients must include identification and treatment of these comorbidities.[@b7-copd-12-3371] The concern of COPD-related comorbidities has been rising in recent years due to their significant negative impact on patient outcome. A "solar system" like COPD comorbidome was introduced by the BODE collaborative group recently, incorporating the prevalence and strength of the association between the disease and risk of death.[@b16-copd-12-3371] The interrelationship between clinical characteristics and comorbidities was also quantified by the same study group in a lung-shaped layout network.[@b34-copd-12-3371]

In the current study, we evaluated commonly found comorbidities in our locality. In all, 80.9% of our patients had coexisting comorbidities, which exceeded those reported in the EPIC and EPOCA studies (39% and 42%, respectively),[@b3-copd-12-3371],[@b18-copd-12-3371] probably due to different patient populations and methodologies. HT, diabetes mellitus, ischemic heart disease and old tuberculosis are the common comorbidities in the current and various local and overseas studies.[@b16-copd-12-3371],[@b17-copd-12-3371],[@b34-copd-12-3371] Three aspects of barriers for comorbidity detection have been described by Maurer et al,[@b35-copd-12-3371] including patient-perceived, physician-perceived and system-level barriers.[@b36-copd-12-3371],[@b37-copd-12-3371] As cumulating evidence is now available for the management of these comorbidities,[@b38-copd-12-3371] a well-structured screening protocol or program-based multimodality COPD care service should be developed. Obesity and advanced age were found to be associated with the presence of comorbidities, as they are believed to be common risk factors shared by COPD and certain comorbidities.[@b39-copd-12-3371]

There were several limitations in our study. First, as an observational study with a self-reporting mechanism, treatment details including reasons for nonadherence and medication change might not be always available due to recall bias. Second, the COPD groupings could be different if the attending physician chose to use one instead of another factor, for example, to use mMRC score instead of CAT score. This difference could affect the choice of pharmacological treatment significantly.[@b40-copd-12-3371],[@b41-copd-12-3371] Third, the sample size was not large enough to predict the effect of treatment nonadherence on mortality, COPD exacerbation and pneumonia due to ICS overuse. Fourth, as our study did not require a thorough screening of comorbidities and no management modification was made to the clinical follow up, there might be a possibility of underreporting of comorbidities. Finally, the study population skewed toward groups B and D due to high mMRC or CAT scores, which signified that the patients were highly selective and this might not completely reflect the usual pattern of disease burden.[@b3-copd-12-3371] This distribution of disease grouping may therefore limit the generalizability of the results.

Conclusion
==========

In summary, the current study involving subjects with typical COPD clinical characteristics demonstrated a suboptimal adherence to GOLD guideline 2011 and overtreatment, especially overprescription of ICS. The most commonly found COPD-related comorbidities also aligned with the trend observed in local and nation-wide observational cohorts.
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![COPD grouping and pharmacological management recommended by GOLD guideline 2011.\
**Notes:** Adapted from Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2011 with permission.[@b7-copd-12-3371] ^a^Treatment options within each choice are mentioned in alphabetical order and therefore not necessarily in order of preference. ^b^Alternative treatment to be used alone or in combination with other options in the first and second choices. ^c^GOLD 1: FEV~1~ ≥80% predicted, GOLD 2: 50%≤ FEV~1~ ≤80% predicted, GOLD 3: FEV~1~ ≤50% predicted and GOLD 4: FEV~1~ \<30% predicted or FEV~1~ predicted plus chronic respiratory failure.\
**Abbreviations:** CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; PDE4i, phosphodiesterase 4 inhibitors; prn, as needed (pro renata); SABA, short-acting β~2~-agonist; SAMA, short-acting muscarinic antagonist.](copd-12-3371Fig1){#f1-copd-12-3371}

![Enrollment and outcomes.](copd-12-3371Fig2){#f2-copd-12-3371}

###### 

Definition of overtreatment and undertreatment for different groups of COPD patients

  ----------------------------------------------------------- ---------------------------------
  Overtreatment (presence of these medication combinations)   
   Group A                                                    LABA + LAMA, any ICS, any PDE4i
   Group B                                                    Any ICS, any PDE4i
   Group C                                                    LABA + LAMA + ICS
  LAMA + ICS                                                  
  Undertreatment (absence of these medication combinations)   
   Group B                                                    LABA, LAMA
   Group C                                                    LAMA, LABA + ICS, LABA + LAMA
   Group D                                                    LABA + ICS, LAMA alone
  LABA + LAMA + ICS                                           
  LABA + ICS + PDE4i                                          
  LAMA + LABA, LAMA + PDE4i                                   
  LAMA + ICS                                                  
  ----------------------------------------------------------- ---------------------------------

**Notes:** "Overtreated" group applies to patients of groups A, B and C using a pharmacological treatment combination more than recommended by the guideline, and "undertreatment" group applies to patients of groups B, C and D using a suboptimal pharmacological treatment combination. ICS alone are considered as undertreatment in groups B, C and D and as overtreatment in group A.

**Abbreviations:** ICS, inhaled corticosteroids; LABA, long-acting β~2~-agonist; LAMA, long-acting muscarinic antagonist; PDE4i, phosphodiesterase 4 inhibitors.

###### 

Baseline sociodemographics and clinical characteristics

  Variable                                        Mean ± SD   n (%)
  ----------------------------------------------- ----------- ------------
  Age, years                                      73.7±8.5    
  Gender                                                      
   Male                                                       413 (92.2)
   Female                                                     35 (7.8)
  Smoking status                                              
   Current smoker                                             65 (14.5)
   Ex-smoker                                                  361 (80.4)
   Nonsmoker                                                  23 (5.1)
  Smoking packs/year (non-smokers excluded)       39.5±32.3   
  Working status                                              
   Employed                                                   39 (8.7)
   Unemployed                                                 6 (1.3)
   Retired                                                    401 (89.9)
  Body weight, kg                                 56.4±11.0   
  Body height, cm                                 162.2±7.3   
  BMI, kg/m^2^                                    21.4±3.8    
  Pre-BD FEV~1~/L                                 1.0±0.5     
  Pre-BD FEV~1~/% predicted                       47.2±19.7   
  Post-BD FEV~1~/L                                1.1±0.5     
  Post-BD FEV~1~/% predicted                      50.8±21.7   
  CAT score                                       13.2±8.1    
  mMRC dyspnea score                              2.1±1.0     
  Number of exacerbations in the last 12 months   1.6±1.9     
  ≥2 exacerbations in the last 12 months                      165 (37.4)
  Baseline COPD group                                         
   A                                                          5 (1.1)
   B                                                          164 (36.4)
   C                                                          8 (1.8)
   D                                                          273 (60.7)

**Abbreviations:** BD, bronchodilator; BMI, body mass index; CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council; SD, standard deviation.

###### 

Use of pharmacological and nonpharmacological treatments by COPD grouping at different visits (by class of treatment)

  Visit                 Visit 1   Visit 2   Visit 3                                                                                                                               
  --------------------- --------- --------- --------- ------ --- ------- ----- ------ --- ------ ----- ------ --- ------- ----- ------ --- ------- ----- ------ --- ------- ----- ------
  Any SABA              5         100.0     156       95.1   8   100.0   266   97.4   3   75.0   147   87.0   1   100.0   210   89.4   3   100.0   156   92.3   3   100.0   198   95.7
  Any SAMA              3         60.0      57        34.8   0   0.0     80    29.3   1   25.0   46    27.2   1   100.0   64    27.2   1   33.3    53    31.4   0   0.0     43    20.8
  LABA only             1         20.0      1         0.6    0   0.0     1     0.4    0   0.0    0     0.0    1   100.0   3     1.3    1   33.3    2     1.2    0   0.0     2     1.0
  LAMA only             0         0.0       6         3.7    0   0.0     6     2.2    0   0.0    1     0.6    0   0.0     4     1.7    0   0.0     2     1.2    0   0.0     3     1.4
  ICS only              1         20.0      25        15.2   1   12.5    13    4.8    0   0.0    11    6.5    0   0.0     15    6.4    0   0.0     22    13.0   0   0.0     8     3.9
  Any LABA              4         80.0      110       67.1   6   75.0    240   87.9   3   75.0   126   74.6   1   100.0   184   78.3   3   100.0   130   76.9   3   100.0   185   89.4
  Any LAMA              2         40.0      82        50.0   7   87.5    174   63.7   2   50.0   88    52.1   0   0.0     136   57.9   2   66.7    90    53.3   3   100.0   149   72.0
  Any ICS               4         80.0      144       87.8   8   100.0   262   96.0   3   75.0   147   87.0   0   0.0     202   86.0   2   66.7    152   89.9   3   100.0   193   93.2
  ICS + LABA            1         20.0      43        26.2   0   0.0     81    29.7   1   25.0   49    29.0   0   0.0     57    24.3   0   0.0     46    27.2   0   0.0     43    20.8
  LABA + LAMA           0         0.0       0         0.0    0   0.0     0     0.0    0   0.0    0     0.0    0   0.0     2     0.9    0   0.0     4     2.4    0   0.0     4     1.9
  LABA + LAMA + ICS     2         40.0      66        40.2   6   75.0    158   57.9   2   50.0   77    45.6   0   0.0     122   51.9   2   66.7    78    46.2   3   100.0   136   65.7
  LABA + LAMA + PDE4i   0         0.0       0         0.0    0   0.0     0     0.0    0   0.0    0     0.0    0   0.0     1     0.4    0   0.0     1     0.6    0   0.0     2     1.0
  Any theophylline      1         20.0      44        26.8   2   25.0    76    27.8   1   25.0   53    31.4   0   0.0     52    22.1   1   33.3    42    24.9   0   0.0     55    26.6
  Any PDE4i             1         20.0      0         0.0    0   0.0     17    6.2    0   0.0    9     5.3    0   0.0     10    4.3    0   0.0     5     3.0    0   0.0     21    10.1
  Any montelukast       0         0.0       1         0.6    0   0.0     0     0.0    0   0.0    0     0.0    0   0.0     1     0.4    0   0.0     0     0.0    0   0.0     0     0.0

**Abbreviations:** ICS, inhaled corticosteroids; ICS + LABA, LABA with ICS together in single or separate inhaler devices; LABA, long-acting (3~2~-agonist; LABA + LAMA, LABA with LAMA together in single or separate inhaler devices; LABA + LAMA + ICS, LABA, LAMA and ICS together in single or separate devices; LABA + LAMA + PDE4i, LABA and LAMA together in single or separate inhaler device with PDE4i; LAMA, long-acting muscarinic antagonist; PDE4i, phosphodiesterase 4 inhibitors; SABA, short-acting (3~2~-agonist; SAM A, short-acting muscarinic antagonist.

###### 

Reasons for change of pharmacological therapy

  Treatment changed                                  Visit 1 (n=446)   Visit 2 (n=407)   Visit 3 (n=380)
  -------------------------------------------------- ----------------- ----------------- -----------------
  Number of patients who had treatment changed (%)   123 (27.6)        123 (30.2)        107 (28.2)
  Reasons                                                                                
   Insufficient disease control, n (%)               104 (84.6)        89 (72.4)         78 (72.9)
   Tolerability issues, n (%)                        9 (7.3)           14 (11.4)         11 (2.9)
   Compliance issues, n (%)                          1 (0.8)           2 (1.6)           5 (1.3)
   Inhaler device issues, n (%)                      6 (4.9)           7 (5.7)           4 (1.1)
   Others, n (%)                                     9 (7.3)           14 (11.4)         10 (2.6)

**Note:** Some patients had more than one reason for change of therapy.

###### 

Adherence rate to GOLD guideline 2011

  Visit   COPD groups   Total number of patients   Adherent, n (%)   Overtreated, n (%)   Undertreated, n (%)
  ------- ------------- -------------------------- ----------------- -------------------- ---------------------
  1       Overall       450                        262 (58.2)        130 (28.9)           58 (12.9)
  A       5             1 (0.2)                    4 (0.9)           N/A                  
  B       164           7 (1.6)                    119 (26.4)        38 (8.4)             
  C       8             0 (0.0)                    7 (1.6)           1 (0.2)              
  D       273           254 (56.4)                 N/A               19 (4.2)             
  2       Overall       409                        195 (47.7)        140 (34.2)           74 (18.1)
  A       4             1 (0.2)                    3 (0.7)           N/A                  
  B       169           1 (0.2)                    137 (33.5)        31 (7.6)             
  C       1             0 (0.0)                    0 (0.0)           1 (0.2)              
  D       235           193 (47.2)                 N/A               42 (10.3)            
  3       Overall       382                        197 (51.6)        136 (35.6)           49 (12.8)
  A       3             1 (0.2)                    2 (0.5)           N/A                  
  B       169           4 (1.0)                    131 (34.3)        34 (8.9)             
  C       3             0 (0.0)                    3 (0.8)           0 (0.0)              
  D       207           192 (50.3)                 N/A               15 (3.9)             

**Note:** The rate of guideline adherence and undertreatment remains similar over 12 months, but there was an increasing trend of overtreatment.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; N/A, not applicable.

###### 

Adherence rate to GOLD guideline 2011 and exacerbation rate

  Treatment adherence    Total   No exacerbation   Exacerbation occurred   Comparison with adherence group on exacerbation
  ---------------------- ------- ----------------- ----------------------- --------------------------------------------------------
  Adherence group        183     57                126                     N/A
  Overtreatment group    86      51                35                      *p*\<0.001[a](#tfn8-copd-12-3371){ref-type="table-fn"}
  Undertreatment group   41      34                7                       *p*\<0.001[a](#tfn8-copd-12-3371){ref-type="table-fn"}

**Note:**

Patients in the adherence group had more exacerbations than those overtreated or undertreated.

**Abbreviations:** GOLD, Global Initiative for Chronic Obstructive Lung Disease; N/A, not applicable.

###### 

Summary of comorbidities by baseline COPD groupings

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Comorbidity, n (%)                  Baseline COPD group by GOLD guideline 2011   *p*-value    Total (N=450)                                                                                                                    
  ----------------------------------- -------------------------------------------- ------------ --------------- ------------ --------------------------------------------------------------------------------------------------- ------------
  Any comorbidities                   3 (60.0)                                     122 (74.4)   6 (75.0)        233 (85.3)   0.033[a](#tfn11-copd-12-3371){ref-type="table-fn"},[b](#tfn12-copd-12-3371){ref-type="table-fn"}\   364 (80.9)
                                                                                                                             0.005[a](#tfn11-copd-12-3371){ref-type="table-fn"},[c](#tfn13-copd-12-3371){ref-type="table-fn"}    

  HT                                  1 (20.0)                                     68 (41.5)    3 (37.5)        111 (40.7)   0.920[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  183 (40.7)

  DM                                  2 (40.0)                                     14 (8.5)     1 (12.5)        36 (13.2)    0.163[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  53 (11.8)

  Old TB                              0 (0.0)                                      18 (11.0)    3 (37.5)        29 (10.6)    1.000[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  50 (11.1)

  IHD                                 0 (0.0)                                      12 (7.3)     0 (0.0)         35 (12.8)    0.080[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  47 (10.4)

  BPH                                 0 (0.0)                                      16 (9.8)     0 (0.0)         30 (11.0)    0.749[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  46 (10.2)

  Hyperlipidemia                      0 (0.0)                                      9 (5.5)      1 (12.5)        18 (6.6)     0.688[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  28 (6.2)

  Cardiac arrhythmia                  0 (0.0)                                      8 (4.9)      0 (0.0)         20 (7.3)     0.420[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  28 (6.2)

  Malignancy other than lung cancer   0 (0.0)                                      5 (3.0)      2 (25.0)        18 (6.6)     0.125[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  25 (5.6)

  Heart failure                       1 (20.0)                                     3 (1.8)      0 (0.0)         19 (7.0)     0.022[a](#tfn11-copd-12-3371){ref-type="table-fn"},[c](#tfn13-copd-12-3371){ref-type="table-fn"}    23 (5.1)

  Old CVA                             0 (0.0)                                      9 (5.5)      0 (0.0)         13 (4.8)     0.822[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  22 (4.9)

  Bronchiectasis                      0 (0.0)                                      2 (1.2)      0 (0.0)         7 (2.6)      0.494[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  9 (2.0)

  Lung cancer                         0 (0.0)                                      1 (0.6)      0 (0.0)         6 (2.2)      0.264[c](#tfn13-copd-12-3371){ref-type="table-fn"}                                                  7 (1.6)

  Others                              0 (0.0)                                      45 (27.4)    4 (50.0)        86 (31.5)                                                                                                        135 (30.0)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Patients of groups B and D had a higher prevalence of comorbidities than those of groups A and C. Comparison between groups A and C was not performed due to the small number of patients.

Clinically significant.

Comparison between all COPD groups.

Comparison between groups B and D.

**Abbreviations:** BPH, benign prostatic hyperplasia; CVA, cerebrovascular accident; DM, diabetes mellitus; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HT, hypertension; IHD, ischemic heart disease; TB, tuberculosis.
